Prokaeva Tatiana, Jayaraman Shobini, Klimtchuk Elena, Burke Natasha, Spencer Brian, Nedelkov Dobrin, Chen Hui, Dasari Surendra, McPhail Ellen D, Pereira Lucas, Payne Michael C, Wong Sherry, Burks Eric J, Sanchorawala Vaishali, Gursky Olga
Amyloidosis Center, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA.
Department of Pharmacology, Physiology & Biophysics, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA.
Biochim Biophys Acta Mol Basis Dis. 2025 Jun;1871(5):167820. doi: 10.1016/j.bbadis.2025.167820. Epub 2025 Mar 29.
Apolipoprotein A-I (apoA-I) plays beneficial roles as the major structural and functional protein on plasma high-density lipoproteins (HDL). However, APOA1 gene mutations can cause protein misfolding and pathologic amyloid deposition in various organs in human hereditary AApoAI amyloidosis, a potentially lethal systemic disease. We report esophageal and duodenal AApoAI amyloidosis in a 56-year-old patient with Barrett's esophagus, a condition involving chronic acid reflux. Amyloid deposits contained full-length apoA-I featuring a novel D20Y mutation identified by gene sequencing and protein mass spectrometry. Genetic analysis of asymptomatic family members revealed autosomal dominant inheritance. Fibril formation by the full-length variant apoA-I rather than its fragments and the location of the mutation in a conserved amyloid-prone N-terminal segment were highly unusual for hereditary AApoA-I amyloidosis. Structural and stability studies of the recombinant D20Y and wild-type apoA-I showed small but significant mutation-induced structural perturbations in the native lipid-free protein at pH 7.4. Major destabilization and aggregation of the variant protein were observed at pH 4.0. We propose that acidic conditions in Barrett's esophagus promoted protein misfolding and amyloid formation by the D20Y variant. These findings expand our understanding of the clinical features and molecular basis of AApoAI amyloidosis and suggest clinical strategies.
载脂蛋白A-I(apoA-I)作为血浆高密度脂蛋白(HDL)上的主要结构和功能蛋白发挥着有益作用。然而,在人类遗传性AApoAI淀粉样变性(一种潜在致命的全身性疾病)中,APOA1基因突变可导致蛋白质错误折叠和在各个器官中出现病理性淀粉样沉积。我们报告了一名患有巴雷特食管(一种涉及慢性胃酸反流的病症)的56岁患者出现食管和十二指肠AApoAI淀粉样变性。淀粉样沉积物含有全长apoA-I,通过基因测序和蛋白质质谱鉴定出一种新的D20Y突变。对无症状家庭成员的基因分析显示为常染色体显性遗传。全长变体apoA-I而非其片段形成原纤维以及该突变位于保守的易于形成淀粉样的N端区域,这在遗传性AApoA-I淀粉样变性中非常罕见。重组D20Y和野生型apoA-I的结构和稳定性研究表明,在pH 7.4时,无脂质天然蛋白中存在微小但显著的突变诱导结构扰动。在pH 4.0时观察到变体蛋白的主要去稳定化和聚集。我们提出,巴雷特食管中的酸性条件促进了D20Y变体的蛋白质错误折叠和淀粉样形成。这些发现扩展了我们对AApoAI淀粉样变性临床特征和分子基础的理解,并提出了临床策略。